WuXi AppTec acquires US clinical research firm
In line with its expansion strategies, Shanghai based biotechnology and medicaldevice developer WuXi AppTec Group has acquired US-based clinical research company Research Point Global (RPG).
The acquisition will help expand WuXi’s clinical research capabilities in the United States and around the world. The deal will combine Research Point with WuXi’s existing China-based clinical development service team.
Upon completion of the acquisition, RPG will become a wholly owned subsidiary of WuXi, with its service integrated with WuXi’s existing Chinabased, 500-member clinical development service team, or a CRO in the traditional sense, plus 1,000 clinical research coordinators under its site management organization (SMO).
WuXi is in an acquisition spree and has kept up its pace of overseas investments, eyeing strategic acquisitions. Earlier this year, it formed an alliance with biopharmaceutical giant AbbVie Inc. and lifesciences startup Genomics Medicine Ireland Ltd. to conduct population genomics research.